anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults: Initiate treatment with a loading dose of 320 mg delivered as two, 2-mL subcutaneous injections of 160 mg each, administered on the same day at two different injection sites. Continue dosing with a once-weekly injection of 160 mg administered as a single, 2-mL subcutaneous injection.

Pediatric patients 12 years to 17 years: Initiate treatment with a loading dose of 4.4 mg/kg, up to a maximum dose of 320 mg, administered as one or two subcutaneous injections, not to exceed single-injection volume of 2 mL per injection site. If the initial dose is given as two injections, administer on the same day at two different sites. Continue dosing with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg, administered as a single subcutaneous injection, up to 2 mL.

If a once-weekly dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.
An anti-cancer composition comprises anti-cancer effective component selected from tyrosine kinase inhibitor and/or bendamustine and slow releasing adjuvant, and can be prepared into slow releasing injection and slow releasing implantable agent. The slow releasing injection also comprises special dissolvant containing suspending agent. The Suspending agent has a viscocity of 100cp-3000cp (at 20deg.C-30deg.C) and is selected from sodium carboxymethylcellulose, and so on. the slow releasing adjuvant is selected from p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP/TC), p(BHET-EOP/TC), p(BHDPT-EOP/TC), p( BHDPT-EOP/TC), p(CHDM-HOP) or p(CHDM-EOP.Slow releasing injection and implantable agent can keep high medicinal concentration in tumour part through slow releasing for over 60 days after being injected or implanted in or around tumour. The anticancer composition may also be prepared into sustained-release implant. It can reduce systemic toxic reaction of anticancer drugs, and also selectively improve the therapeutic effect of non-operative therapy such as chemotherapy.
<P>PROBLEM TO BE SOLVED: To provide a functional beverage through which extract oil of cypress family plants can be easily taken so as to prevent transmission of pathogens such as influenza virus.  <P>SOLUTION: The functional beverage is obtained through making a beverage such as green tea contain extract from the cypress family plants. The extract contains the extract oil of the cypress family plants. The extract oil contains lipophilic components in the extract obtained through subjecting pulverized or powdered cypress family plants to steam distillation. The beverage further contains tea-leaf extraction.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
In accordance with the present invention, there are provided targeted loss of function mutant mice which express less than endogenous levels of at least one member of the steroid/thyroid superfamily of receptors in at least one specific tissue type. For example, mutations in the RXRalpha gene in mouse germlines are lethal in the embryonic stage between E13.5 and E16.5 when bred to homozygosity. The major defect responsible for this lethal effect is hypoplastic development of the ventricular chambers of the heart, which is manifest as a grossly thinned ventricular wall with concurrent defects in ventricular septation. This phenotype is identical to a subset of the effects of embryonic vitamin A deficiency, and therefore establishes RXRalpha as a genetic component of the vitamin A signaling pathway in cardiac morphogenesis. The cardiac outflow tracts and associated vessels, which are populated by derivatives of the neural crest and which are also sensitive to vitamin A deficiency, are normal in homozygous embryos, indicating the genetic independence of ventricular chamber development. Hepatic differentiation was dramatically but transiently retarded, yet is histologically and morphologically normal. These results ascribe an essential function for the RXRalpha gene in embryonic development, and provide the first evidence of a requirement for RXR in one of its predicted hormone response pathways.
Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
INTRODUCTION: For women presenting with breast cancer during pregnancy, treatment guidelines were historically restricted to only surgical treatment. Over the past decades, chemotherapy administered during pregnancy has been gradually introduced. Although breast cancer treatments during ongoing pregnancy have been deemed safe, detailed information on potential obstetric risks is lacking. We aimed to assess the risk of adverse obstetric and perinatal outcomes of breast cancer in pregnancy and within 1 year postpartum and in relation to trimester at breast cancer diagnosis, tumor stage, and cancer treatment during pregnancy.
MATERIAL AND METHODS: Population-based matched study. Women diagnosed with breast cancer during pregnancy in 1973-2017 were identified in the Swedish Cancer Register and the Medical Birth Register, with additional information from the National Quality Register for Breast Cancer. Each birth with maternal breast cancer (n = 208 pregnant, n = 672 postpartum) was matched by age, calendar year, and birth order to 10 unexposed births from cancer-free women in the population (n = 2080 and n = 6720). Adjusted conditional logistic and multinomial regression models were used to estimate odds ratios and relative risk ratios, commonly denoted relative risks (RR) with 95% confidence intervals (CI), of adverse obstetric and perinatal outcomes.
RESULTS: Breast cancer during pregnancy was associated with higher risks of preterm birth, both planned (RR 67.1, 95% CI 33.2-135.6) and spontaneous preterm birth (RR 3.8, 95% CI 2.0-7.5), and low birthweight (<2500 g: RR 7.5, 95% CI 4.9-11.3). The associated risks were higher if the breast cancer was diagnosed in the second trimester, and of similar magnitude irrespective of stage and treatment groups. There was a higher risk of low birthweight for gestational age (<25th centile) if breast cancer was diagnosed in the first trimester (RR 2.8, 95% CI 1.1-7.3). Risks of other pregnancy complications were similar to those of unexposed women, as were risks of neonatal mortality and malformations. Postpartum breast cancer was only associated with bleeding during pregnancy (RR 1.6, 95% CI 1.0-2.8).
CONCLUSIONS: Preterm birth and related adverse outcomes were more common in women diagnosed with breast cancer during pregnancy. Reassuringly, breast cancer was not associated with other maternal pregnancy complications or adverse outcomes in children.
Early life stress (ELS) affects neurogenesis and spatial learning, and increases neuroinflammation after a pediatric mild traumatic brain injury (mTBI). Previous studies have shown that ELS has minimal effects in juveniles but shows age-dependent effects in adults. Hence, we aimed to evaluate the effects of ELS in adult male rats after an mTBI. Maternal separation for 180 min per day (MS180) during the first 21 post-natal (P) days was used as the ELS model. At P110, the rats were subjected to a mild controlled cortical impact injury (2.6 mm) or sham surgery. Spatial learning was evaluated in the Morris water maze (MWM) 14 days after surgery and both microglial activation and neurogenesis were quantified. The results indicate that MS180 + mTBI, but not control (CONT) + mTBI, rats show deficiencies in the acquisition of spatial learning. mTBI led to comparable increases in microglial activation in both the hilus and cortical regions for both groups. However, MS180 + mTBI rats exhibited a greater increase in microglial activation in the ipsilateral CA1 hippocampus subfield compared with CONT + mTBI. Interestingly, for the contralateral CA1 region, this effect was observed exclusively in MS180 + mTBI. ELS and mTBI independently caused a decrease in hippocampal neurogenesis and this effect was not increased further in MS180 + mTBI rats. The findings demonstrate that ELS and mTBI synergistically affect cognitive performance and neuroinflammation, thus supporting the hypothesis that increased inflammation resulting from the combination of ELS and mTBI could underlie the observed effects on learning.
Kidney transplantation in children with end-stage kidney disease significantly enhances survival and quality of life but poses unique challenges related to chronic immunosuppressive therapy. In fact, despite being essential for preventing organ rejection, immunosuppressive therapy can have significant side effects specific to pediatric patients, such as adverse impacts on physiological growth, puberty, and fertility. The resulting short stature and delayed or incomplete pubertal development can profoundly affect young patients' psychological and social well-being, impacting self-esteem and overall quality of life, and may significantly hamper compliance and therapeutic adherence. Most studies on immunosuppression in pediatric kidney transplant recipients focus on general side effects and outcomes like long-term graft survival or acute complications. On the other side, there is limited evidence in the current literature on the specific issues of growth, puberty, and fertility in this patient population. In this pragmatic review, we aimed to summarize the most relevant information available on these critical aspects of post-transplant management in pediatric patients, also providing some practical indications on management strategies for minimizing these often neglected but still important complications.
Inflammation is the most common disease in humans. Alcohol has been part of human culture throughout history. To avoid alcohol prompting inflammation to develop into a more serious disease, it is important for human health to explore the effects of alcohol on the development of inflammation.Endogenous sulfur dioxide (SO2) is considered an important regulator of the development of inflammation and is involved in the entire development process of inflammation. Taken together, it is of great significance to explore the impact of alcohol on the development process of inflammation through changes in SO2 concentration in the inflammatory microenvironment. Herein, we report the development of a molecular tool (Nu-SO2) with rapid (5 s) response to the important inflammatory modulator sulfur dioxide (SO2) for the diagnosis of inflammation, assessment of therapeutic effects, and evaluation of the development process of alcohol-induced inflammation. The rationality of Nu-SO2 was confirmed through molecular docking calculations, density functional theory (DFT) theoretical calculations, DNA/RNA titration experiments and co-localization experiments. Furthermore, Nu-SO2 was effectively applied for specific response and highly sensitive visualization imaging of SO2 in solution, cells and mice. Importantly, Nu-SO2 was successfully used to diagnose lipopolysaccharide-induced inflammation in cells and mice and evaluate the efficacy of dexamethasone in treating inflammation. More significantly, based on the excellent performance of Nu-SO2 in dynamically reporting the further development of inflammation in mice triggered by alcohol, we successfully elucidated the "anti-inflammatory and pro-inflammatory" trend in the development of inflammation caused by alcohol stimulation. Thus, this work not only advances the research on the relationship between alcohol, inflammation and SO2, but also provides a new non-invasive assessment method for the development mechanism of inflammation induced by external stimuli and the precise diagnosis and treatment of drug efficacy evaluation.
The invention relates to skin-care liquid soap and a preparation method thereof, and belongs to the field of processing technology of daily chemical products. The liquid soap comprises 15-16 parts of sodium dodecyl sulfate, 13-15 parts of sodium alcohol ether sulphate, 3-5 parts of sodium carboxymethylcellulose, 3-5 parts of lauryl dimethylamine oxide, 11-14 parts of an alkylolamide, 12-15 parts of glycerol, 6-8 parts of water-soluble lanolin, 6-8 parts of camellia oil and 20-30 parts of distilled water. The liquid soap is prepared by steps of adding the glycerol into a beaker, adding the CMC, stirring uniformly with a glass rod, then stirring by a mechanical stirrer at a speed of 2500 r/min, adding water while stirring for 5-10 min, and allowing the mixture to stand for 2-3 h; adding dissolved water-soluble lanolin and the camellia oil, adding the dissolved AESA 5-10 min later, adding the K12 3-5 min later and allowing the mixture to stand; adding the 6501 and the OB-2 after foam disappears, and stirring for 20-30 min; and allowing the mixture to stand and ageing to achieve self-equalization of the system. The liquid soap prepared has good cleaning effects and has skin care functions. The preparation method is simple. The liquid soap is suitable for industrial production.
Prior to initiation of the study, participants will have a screening visit to complete informed consent and health history. The history for females will include their last date for menstruation and/or birth control method to take into consideration the effects of ovulation on water retention. During this visit we will measure heart rate, blood pressure, height, weight. Females will be administered a urine pregnancy test.

Participants must refrain from vigorous exercise within 24 hours of study visit. Participants will fast (food) overnight for 10h prior to initiation of test. Upon waking they are asked to empty their bowel \& bladder. They can consume one 8oz cup of coffee or other liquid. They will present at 7-8am at which time they will be asked to empty their bladder again. After resting for 5 minutes baseline vitals will be taken, including blood pressure, heart rate, weight, bioimpedance. Urinalysis dipstick for protein/blood/glucose and i-STAT measurement for creatinine and electrolytes on Visit 1 to confirm eligibility. For Visit 2 and Visit 3, the participant will be asked to review medical history and any change in status may warrant an additional baseline creatinine and blood/protein test to confirm eligibility. Additional food or beverage will not be allowed throughout the study period. All studies will be repeated in the same subject using either Buoy (intervention) or water (control) or Nuun (intervention). Urine will be collected at four specific timepoints during the intervention and the volume will be recorded. If participants need to urinate between scheduled collection times, urine will be collected, volume recorded, and combined with the urine collection of the following timepoint. These urine samples will be measured and a fraction of it will be sent to the lab to be tested for the following electrolytes: sodium, potassium, chloride and urine osmolarity. Urine creatinine will also be tested at these timepoints.
The protocol will be explained during hospitalisation for each donor infected by SARS-CoV-2. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10\^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10\^9.
Cerebellar amyloid-β (Aβ) plaques are a component of the diagnostic criteria used in Thal staging and ABC scoring for Alzheimer disease (AD) neuropathologic change. However, Aβ deposits in this anatomic compartment are unique and under-characterized; and their relationship with other pathological findings are largely undefined. In 73 cases of pure or mixed AD with an A3 score in the ABC criteria, parenchymal (plaques) and vascular (cerebral amyloid angiopathy [CAA]) cerebellar Aβ-42 deposits were characterized with respect to localization, morphology, density, and intensity. Over 85% of cases demonstrated cerebellar Aβ-42 parenchymal staining that correlated with a Braak stage V-VI/B3 score (p < 0.01). Among the 63 with cerebellar Aβ-42 deposits, a diffuse morphology was observed in 75% of cases, compact without a central dense core in 32%, and compact with a central dense core in 16% (all corresponding to plaques evident on hematoxylin and eosin staining). Cases with Purkinje cell (PC) loss showed higher proportions of PC layer Aβ-42 staining than cases without PC loss (88% vs 44%, p = 0.02), suggesting a link between Aβ-42 deposition and PC damage. Among all 73 cases, CAA was observed in the parenchymal vessels of 19% of cases and in leptomeningeal vessels in 44% of cases.
PCT No. PCT/JP95/01577 Sec. 371 Date Feb. 6, 1997 Sec. 102(e) Date Feb. 6, 1997 PCT Filed Aug. 8, 1995 PCT Pub. No. WO96/04914 PCT Pub. Date Feb. 22, 1996The invention relates to a medicinal composition comprising a triazine derivative of the following general formula [I]or a solvate thereof, or a salt thereof, as an active ingredient. In the above formula, R1 and R2 may be the same or different and each represents hydrogen, unsubstituted or substituted alkyl aralkyl, or alkenyl, or jointly represent cyclic amino (NR1R2) in combination with the adjacent nitrogen atom. The cyclic amino may contain nitrogen, oxygen, or sulfur as a ring member in addition to the adjacent nitrogen and may be further substituted. Excluded is the case in which NR1R2 is NH2. The compound of the invention is useful as a therapeutic drug for hepatitis.
Background: The natural history of venous malformation (VM) and Klippel-Trenaunay Syndrome (KTS) has not been quantitatively studied. To obtain benchmarks to guide designing clinical trials to assess safety and efficacy of novel drug candidates, the clinical course of the patients was followed for 6 months. Methods and Results: This is a multicenter prospective observational study evaluating the change rate in lesion volume from baseline with magnetic resonance images, as the primary endpoint. In addition, disease severities, performance status (PS), pain visual analog scale (VAS) score, quality of life (QoL), infections, and coagulation markers were also evaluated. Thirty-four patients (VM = 17, KTS = 17, 1-53 of age; median 15.9 years) with measurable lesion volume were analyzed. There was no statistically significant difference in the lesion volume between baseline and day 180, and the mean change rate (standard deviation) was 1.06 (0.28). There were no baseline characteristics that affected the change in lesion volume over 6 months. However, there were patients who showed more than 20% volume change and it was suggested that the lesion volume was largely impacted by local infection. There were no statistically significant changes in pain VAS score, severity, PS, QoL score, D-dimer, and platelet count over 6 months within all patients analyzed. Conclusion: The results showed the representative natural course of VM and KTS for a 6-month period with objective change of lesion volume and other factors, suggesting that it is scientifically reasonable to conduct a Phase 2 proof-of-concept study without a placebo arm, using the results of this study as the control. Clinical Trial Registration: NCT04285723, NCT04589650.
Participants will be recruited from multiple locations, including NorthShore University Health System's Kellogg Cancer Center (KCC) and local community organizations (e.g., UsToo meetings, Cancer Wellness Center). Participating physician researchers will identify their eligible patients from the electronic medical record and will mail them a letter of invitation to learn more about the study and consider enrolling. Each participant will be e-mailed a link to the baseline questionnaire. After baseline completion, participants will be randomized, using an online random number generator, to the online course or face-to-face course. Course orientation for both groups will be held on the same night, but at different times. The separate orientations will be scheduled with a thirty minute break in between, in order to prevent intermixing of the groups and potential dissatisfaction among participants about their assigned group. In the orientation for the online class, participants will become familiar with the online video conferencing program Zoom, be introduced to other group participants, and receive a clear overview of what to expect for the 4-week mindfulness course. In the orientation for the face-to-face class, participants will be introduced to other group participants and receive a clear overview of what to expect for the 4-week mindfulness course. Participants will meet for approximately 2.5 hours each week for 4 weeks online or face-to-face. In addition, a face to face half day retreat will occur after the third class, in which participants from both face to face and online courses may attend. In the event that a participant unexpectedly misses a class, the instructor will follow-up with them and review the material covered in class. The class instructor may contact participants up to 3 times to review class expectations and teachings prior to or during the 4-week program. Participants will once again be asked to complete the online assessment.
NEW MATERIAL:A compound expressed by formula I (n is 1 of 2; A represents ligand expressed by formula VII). EXAMPLE:alpha-Glycolato-(3RS)-3-aminopyrrolidine-platinum (II). USE:An antitumor agent. PREPARATION:A cyclic amine expressed by formula II is reacted with a compound expressed by formula III at ambient temperature - 100 deg.C for 5-50hr using water as a solvent to afford a novel halogeno-platinum complex expressed by formula IV. The amount of the compound expressed by formula II used is 1-1.5mol based on 1mol compound expressed by formula III. Then the compound expressed by formula IV is reacted with silver nitrate normally in water as a solvent at ambient temperature for 1-4 days while shielding light to afford the compound expressed by formula V. The amount of the silver nitrate used is 2-2.2mol based on 1mol compound expressed by formula IV. Then an aqueous solution of the compound expressed by formula V is treated with an anion- exchange resin (OH type) to form a compound expressed by formula VI, which is further reacted with glycolic acid.